# Humana account plan

> Humana is a U.S. health insurer focused on Medicare Advantage, with CenterWell care services, 2025 revenues of $129,664 million and 67,060 associates.

## At a glance

Humana provides health insurance, mainly Medicare Advantage, stand-alone prescription drug plans, Medicaid and TRICARE military services, and runs CenterWell, which offers senior primary care, home health and pharmacy services. Government programmes accounted for approximately 93% of its 2025 premiums and services revenue. In 2025 total revenues were $129,664 million and net income $1,203 million, with approximately 67,060 associates at December 31, 2025. Medical membership reached 17,912,200 at June 30, 2026.

## Business units

- **Insurance segment** (96.3% of 2025 consolidated premiums and services revenue ($123,842 million)): Individual and group Medicare Advantage, stand-alone PDP (including the Humana-Walmart plan), Medicaid contracts, Medicare Supplement, specialty benefits, TRICARE administration and the PBM. Led by George Renaudin, President, Insurance, with Aaron C. Martin as President, Medicare Advantage. Individual MA membership grew 23.4% to 6,453,700 at June 30, 2026.
- **CenterWell segment** ($22,473 million of 2025 total revenues): Pharmacy solutions, value-based senior primary care (398 centres and approximately 622,000 patients at June 30, 2026) and home health in 37 states, serving Humana and third-party payors. Led by Sanjay K. Shetty, M.D.; Q2 2026 income from operations rose 35.5% to $466 million.

## Strategic priorities

- **Return to a sustainable MA margin by 2028**: Humana is committed to returning to a sustainable pre-tax margin of at least 3% in 2028 and unlocking the earnings potential of the business by 2028, as laid out at its 2025 Investor Day.
- **Top Quartile Star Ratings**: After a decline in 2025 Star Ratings, Humana exceeded its goal of Top Quartile results in the 2027 Star Ratings (Bonus Year 2028) released on October 8, 2026.
- **Membership growth across Medicare**: Approximately 25% individual MA growth expected in 2026, about 1,000,000 PDP members and about 150,000 group MA members; a statewide Illinois Medicaid contract starts in January 2027.
- **Grow CenterWell primary care**: 60 to 70 new centres and 120,000 to 140,000 net new patients planned for 2026 through M&A, same-store growth, IPA expansion and de novo openings.
- **Cost structure transformation**: Value creation initiatives re-align the cost structure, operating model and technology footprint; the consolidated operating cost ratio is guided to 10% plus or minus 25 bps in 2026, down from 11.5% adjusted in 2025.

## Latest results

In Q2 2026 (quarter ended June 30), total revenues rose 26.2% to $40,867 million, driven by Medicare membership growth and higher per-member premiums, and net income attributable to Humana was $694 million against $545 million. The consolidated benefit ratio rose to 91.1% from 89.7%, reflecting the Star Ratings revenue headwind and new members running at a higher benefit ratio, while the operating cost ratio fell 120 basis points to 9.8%. For the six months, revenues were $80,515 million (+24.8%). Humana affirmed FY 2026 Adjusted EPS of at least $9.00, down from $17.14 in 2025, and holds a virtual investor update on December 10, 2026.

## Investments and deals

- **MaxHealth acquisition**: A Florida primary care platform acquired on February 13, 2026 for approximately $908 million net of cash acquired.
- **Value creation initiatives**: Charges of $449 million in 2025, including $329 million of severance, and $154 million in H1 2026, with more expected.
- **Capital expenditure**: Net capital expenditures of $523 million in 2025, mainly information technology and primary care facilities, and $253 million in H1 2026.
- **Gentiva divestiture**: Agreement to divest all or substantially all of its minority interest in Gentiva, valued at approximately $900 million.
- **Contingent capital**: $1.5 billion of P-Caps facilities established in May 2026 and $1.0 billion of junior subordinated notes issued in March 2026.

## Challenges and risks

- **Star Ratings revenue headwind**: The number of MA plans rated 4-star or higher declined significantly in 2025, cutting 2026 quality bonus payments and earnings.
- **Medical and drug cost trend**: Cost trend is expected in the high single digits in 2026, with pharmacy in the low double digits, and initial 2026 guidance assumed individual MA margins slightly below breakeven.
- **Regulatory and audit risk**: CMS RADV audits, IRA Part D changes and possible restrictions on vertically-integrated arrangements; AI/ML use is listed as a source of regulatory risk.
- **Revenue concentration**: 83% of 2025 premiums and services revenue came from federal government contracts, including 14% from Florida individual MA contracts.
- **Litigation**: A DOJ False Claims Act complaint over payments to call-centre broker partners, a TCPA class action and a securities class action.

## What leadership says

> "behave more like a consumer health care company, to the degree that there is such a thing in the U.S. right now, as opposed to a traditional insurance company." — Jim Rechtin, President and CEO, Fortune interview, November 10, 2025

> "we have almost no tools to collect feedback from our customers." — Jim Rechtin, President and CEO, Fortune interview, November 10, 2025

> "Billing and collecting costs too much. Distribution costs too much." — Jim Rechtin, President and CEO, Fortune interview, November 10, 2025

> "we use AI tools to get to a faster yes. The nos go to a doctor" — Jim Rechtin, President and CEO, Fortune interview, November 10, 2025, on prior authorization


## Where a supplier can help

- **Customer feedback and experience tools**: The CEO wants Humana to behave like a consumer health care company and says it has almost no tools to collect customer feedback, which fits the Star Ratings priority.
- **Administrative cost reduction**: The cost-structure transformation and the CEO's view that billing, collecting and distribution cost too much open room for revenue-cycle, automation and outsourcing suppliers.
- **Compliant AI for sales and care**: AI is used in prior authorization and broker tools while AI/ML use is a listed regulatory risk, so AI governance and audit tooling is relevant.
- **Primary care roll-out**: Opening 60 to 70 centres and integrating MaxHealth calls for clinic fit-out, staffing, scheduling and clinician-productivity solutions.
- **Risk-adjustment and audit readiness**: RADV audits of all eligible MA contracts every year create demand for coding accuracy and documentation support.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Humana Annual Report on Form 10-K, fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm)

Annual report · 2026-02-19

- Humana (Louisville, Kentucky) is a U.S. health company organised in two segments: Insurance (Humana health plans, mostly Medicare) and CenterWell (pharmacy, primary care and home health). About 15 million medical members and 4.7 million specialty members at December 31, 2025; approximately 67,060 associates.
- FY2025 total revenues $129,664 million (+10.1%); income from operations $2,704 million; net income $1,203 million, diluted EPS $9.84 vs $9.98. Benefit ratio 90.2%, operating cost ratio 12.0%.
- Extreme dependence on government programs: Medicare, military services and Medicaid were approximately 93% of premiums and services revenue; individual Medicare Advantage premiums alone were $90,403 million, 70.3% of consolidated premiums and services revenue, and Florida MA contracts 14%.
- Individual Medicare Advantage membership fell 7.3% to 5,249,300 after exits from unprofitable plans and counties; for 2026 Humana anticipates net individual MA growth of approximately 25%, group MA growth of about 150,000 and stand-alone PDP growth of about 1,000,000 members.
- CenterWell total revenues $22,473 million (+12.7%), mostly intersegment ($17,657 million); external revenues +39.0% to $4,816 million. Primary care runs 350 clinics with about 1,300 providers and about 491,100 patients.
- Multi-year transformation ("value creation initiatives") cost $449 million in 2025, including $329 million of severance; the Employer Group Commercial Medical Products business exit was finalised in 2025.
- Key risks: the significant decline in 2025 Star Ratings (lawsuit lost in October 2025, under appeal), the CMS RADV audit rule (vacated by a Texas court in September 2025, government appeal pending), medical cost trends, and the DOJ False Claims Act complaint over broker payments.
- Acquired a primary care business for approximately $941 million on February 13, 2026; credit ratings BBB (S&P) and Baa2 (Moody's).

### [Humana Quarterly Report on Form 10-Q, quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm)

Interim report · 2026-07-29

- Q2 2026 total revenues $40,867 million (+26.2%); H1 2026 $80,515 million (+24.8%), driven by Medicare membership growth, higher MA benchmark funding and the IRA's Part D direct subsidy, partly offset by the Bonus Year 2026 Star Ratings headwind.
- Q2 net income attributable to Humana $694 million, diluted EPS $5.73 (vs $4.51); H1 EPS $15.55 (vs $14.81).
- Membership jumped: individual Medicare Advantage 6,453,700 (+23.4% year on year), group MA 727,200 (+27.6%), stand-alone PDP 3,946,400 (+62.6%); total medical membership 17,912,200 (+20.7%).
- Q2 consolidated benefit ratio rose to 91.1% (89.7%), because of the Star Ratings headwind and new members running at a higher benefit ratio; operating cost ratio fell to 9.8% (11.0%) on operating leverage and cost cutting.
- Insurance segment Q2 income from operations $820 million (+7.0%); CenterWell $466 million (+35.5%), with CenterWell total revenues of $6,790 million (+22.6%) and primary care external revenue +63.5%.
- MaxHealth, a Florida primary care platform, was acquired on February 13, 2026 for approximately $908 million net of cash.
- Balance sheet: $1.0 billion of junior subordinated notes issued in March 2026, $1.5 billion of P-Caps contingent capital in May 2026; statutory capital of approximately $15.5 billion versus $8.2 billion required.

### [Humana Second Quarter 2026 Prepared Management Remarks](https://www.sec.gov/Archives/edgar/data/49071/000004907126000045/a2q2026humanaincpostedrema.htm)

Executive talk · Jim Rechtin, President and Chief Executive Officer · 2026-07-29

- Q2 2026 Adjusted EPS of $7.61, "at the high end" of guidance; FY 2026 guidance of "at least $9.00" Adjusted EPS affirmed, with an Insurance segment benefit ratio of 92.75% plus or minus 25 bps and an operating cost ratio of 10.0% plus or minus 25 bps.
- The 2027 individual MA bids are designed to drive "meaningful progress" towards a "sustainable pre-tax margin of at least 3% in 2028", the target behind "unlocking the earnings potential of the business by 2028".
- Medical and pharmacy cost trends are in line with the "high single digit" expectation, with slight favorability in inpatient care, concentrated among members of value-based providers.
- Year-to-date membership growth: individual MA +1,204,000 (23%), group MA +159,000 (28%), PDP +1,139,000 (50%), Medicaid +93,000.
- CenterWell Primary Care serves approximately 622,000 patients (+27% since December 2025) in 398 centers, helped by The Villages Health and MaxHealth acquisitions.
- New Medicaid wins: a statewide Illinois HealthChoice contract from January 2027 and the Florida contract extended to January 31, 2035; Texas and Georgia awards still face procurement challenges.
- Capital: $1.5 billion of P-Caps contingent capital; agreement to divest the Gentiva minority interest (valued at approximately $900 million); debt to capitalization 42.7%, against a long-term target of approximately 40%.
- A virtual investor update on December 10, 2026 will mark progress against the 2025 Investor Day framework.

### [Humana Fourth Quarter 2025 Prepared Management Remarks (2026 outlook)](https://www.sec.gov/Archives/edgar/data/49071/000004907126000005/a4q2025humanaincpostedrema.htm)

Executive talk · Jim Rechtin, President and Chief Executive Officer · 2026-02-11

- FY 2025 Adjusted EPS of $17.14, above initial guidance of "approximately $16.25"; FY 2026 Adjusted EPS guidance of "at least $9", the decline driven by the Bonus Year 2026 Star Ratings headwind. Guidance is deliberately more conservative than usual.
- The 2026 Annual Election Period added approximately 1 million individual MA members (20%); retention improved by over 500 bps; over 70% of new sales were switchers from competitor plans and nearly 30% were former Humana members.
- About 45% of MA members are expected in 4+ Star contracts in 2026; the Stars goal is Top Quartile results in Bonus Year 2028.
- Individual MA margin expected to double in 2026 on a Stars-normalised basis, but "slightly below breakeven" all in; core medical plus pharmacy cost trend expected in the high single digits.
- Group MA adds large clients (a large airline, Kentucky's Teacher Retirement System, Alabama PEEHIP), with about 150,000 growth and margin repair through recontracting; PDP is expected to add about 1 million members.
- Medicaid footprint spans 13 states (Georgia and Texas to launch in 2027); CenterWell Primary Care plans 60 to 70 new centres and 120,000 to 140,000 net new patients in 2026.
- Consolidated operating cost ratio targeted at 10% (from 11.5% adjusted in 2025); minimal share buybacks, flat dividend, small to mid-sized M&A mainly in CenterWell, and a long-term debt-to-capital target of about 40%.

### [From the Peace Corps to the boardroom: Humana CEO Jim Rechtin on listening and leading (Fortune)](https://www.fortune.com/article/humana-ceo-jim-rechtin-health-insurance-medicare/)

Executive talk · Jim Rechtin, President and Chief Executive Officer · 2025-11-10

- Rechtin wants Humana to "behave more like a consumer health care company", not a traditional insurer built around managing transactions and pricing risk.
- He admits Humana is "not where we want to be": when Humana realised it had fallen behind on Star Ratings "we only had three months to fix it"; getting Star Ratings right is "number one".
- His three priorities: Star Ratings (customer experience and clinical quality), "tech enablement" to engage members and run more efficiently, and a differentiated experience (simpler product, easier preventive care, a streamlined prior authorization process, cost transparency with Epic).
- On AI: ambient listening for CenterWell doctors, "Agent Assist" for brokers selling Medicare Advantage, and AI in prior authorization to "get to a faster yes", while denials go to a doctor; consumers should interact with AI directly "probably three years from now".
- He sees Humana's edge in serving seniors with an individual product plus its own primary care, home health and medication distribution, to act on both cost and quality.
- On policy: fiscal pressure on health spending will continue, against "an active voter block that really loves Medicare and Medicare Advantage"; Humana wants an active role in guiding consumers' decisions.

### [Humana Form 8-K: 2027 Medicare Advantage Star Ratings and 2026 guidance affirmation](https://www.sec.gov/Archives/edgar/data/49071/000004907126000057/hum-20261009.htm)

Report · 2026-10-09

- Based on final 2027 Medicare Advantage Star Ratings (Bonus Year 2028) released by CMS on October 8, 2026, Humana says it "has exceeded its goal of Top Quartile results" (Stars revenue per member per month 10% above the peer-group median).
- The peer group is Centene, CVS, Elevance, HCSC and United.
- Humana will still price products and benefits assuming roughly Top Quartile performance; it treats part of the outperformance as one-time, to be used for one-time investments and return to shareholders.
- Details of the 2028 one-time benefit will come before or with the 2028 guidance on the Q4 2027 earnings call.
- FY 2026 Adjusted EPS guidance of at least $9.00 affirmed; a virtual investor update on December 10, 2026 will mark progress against the 2025 Investor Day framework.

## Questions about Humana

### What does Humana do?

Humana sells health insurance, mainly Medicare Advantage, prescription drug plans and Medicaid, and runs CenterWell senior primary care, home health and pharmacy services.

### What was Humana's revenue in 2025?

Total revenues were $129,664 million in 2025 (+10.1%), with net income of $1,203 million.

### How many employees does Humana have?

Approximately 67,060 associates at December 31, 2025.

### Who leads Humana?

James A. Rechtin has been President and CEO since July 1, 2024; Celeste M. Mellet has been CFO since January 2025.

### What is Humana's strategy?

Humana aims to return to a sustainable MA pre-tax margin of at least 3% in 2028 through membership growth, Top Quartile Star Ratings, CenterWell expansion and cost discipline.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
